Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

144.23
-0.4000-0.28%
Pre-market: 143.19-1.0400-0.72%07:00 EDT
Volume:3.72M
Turnover:536.55M
Market Cap:178.94B
PE:-55.16
High:146.14
Open:145.11
Low:142.60
Close:144.63
52wk High:157.29
52wk Low:112.82
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.71
T/O Rate:0.30%
Dividend:3.22
Dividend Rate:2.23%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.13
PE(LYR):21.27

Loading ...

US Research Roundup-Allstate, Caribou Biosciences, Zscaler

Reuters
·
3 hours ago

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
4 hours ago

Gilead : JP Morgan Raises Target Price to $170 from $160

THOMSON REUTERS
·
6 hours ago

Moderna Inc. Stock Slips 7.8%, Underperforms Peers

Dow Jones
·
14 hours ago

Cognizant, Gilead Sign 5-Year Tech Extension Covering DevOps, AI Tools

MT Newswires Live
·
Yesterday

Cognizant announces five-year extension of its work with Gilead Sciences

TIPRANKS
·
Yesterday

Cognizant - to Support Gilead's Devops and AI Tools Across Selected Technology Programs

THOMSON REUTERS
·
Yesterday

Cognizant Expands AI-Enabled Devops Capabilities for Gilead Sciences

THOMSON REUTERS
·
Yesterday

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Reuters
·
Yesterday

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Yesterday

Moderna Inc. Stock Rises 6.9%, Outperforms Peers

Dow Jones
·
Yesterday

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
Oct 05

Nurix Extends Gilead Collaboration for Oncology Program

Reuters
·
Oct 05

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS
·
Oct 05

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS
·
Oct 05

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
Oct 05

Nurix - Retains Co-Development and 50/50 Profit Sharing Options on Two U.S. Programs

THOMSON REUTERS
·
Oct 05

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05